Cidara Therapeutics reports Q4 EPS (4c), consensus (10c)

Reports Q4 revenue $17.6M, consensus $11.54M. Cash and cash equivalents totaled $35.8M as of December 31, 2023, compared with $32.7M as of December 31, 2022. “2023 included significant accomplishments throughout our business within both our Cloudbreak drug-Fc conjugate and our REZZAYO programs,” said Jeffrey Stein, president and CEO. “With respect to our DFC platform, we continue to generate and present compelling data from our oncology programs as well as our CD388 influenza program partnered with Janssen. We have multiple key catalysts expected this year, including the filing of an Investigational New Drug Application in mid-2024 for CBO421, a potential best-in-class inhibitor of CD73. We recently presented promising new data on CD73/PD-1 multispecific DFC, CCR5-targeting DFC and CBO421 at the American Association for Cancer Research Annual Meeting.”